1 / 31

Pediatric Acute Myelogenous Leukemia (AML)

Pediatric Acute Myelogenous Leukemia (AML). Faculty. Multi-Step Pathogenesis. Incidence. Risk Factors: Inherited Predisposition. Risk Factors: Environmental / Acquired. AML FAB Classification*. WHO Classification of AML. WHO Classification of AML. Clinical Presentation.

danil
Download Presentation

Pediatric Acute Myelogenous Leukemia (AML)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatric Acute Myelogenous Leukemia (AML)

  2. Faculty

  3. Multi-Step Pathogenesis

  4. Incidence

  5. Risk Factors: Inherited Predisposition

  6. Risk Factors: Environmental / Acquired

  7. AML FAB Classification*

  8. WHO Classification of AML

  9. WHO Classification of AML

  10. Clinical Presentation

  11. Clinical Presentation

  12. Extramedullary Disease

  13. Extramedullary Disease

  14. Diagnostic Workup

  15. Molecular Alterations

  16. Cytogenetics

  17. Bone Marrow MorphologyBlasts Compared to Normal Cells

  18. Bone Marrow Morphology AML Blasts with Auer Rods

  19. Cytogenetic Abnormalities in AML

  20. Diagnostic Workup

  21. Potential Risk Factors

  22. Outcomes: Age5-Year Survival

  23. Outcomes: Down Syndrome

  24. Outcomes: Cytogenetics

  25. Prognostic Factors: Unfavorable

  26. Molecular Alterations FLT3 Internal Tandem Duplication (ITD)

  27. Outcomes: FLT3-ITD

  28. Prognostic Factors: Disease Response

  29. Outcomes: Impact of MRD

  30. Outcomes: Impact of Treatment Response Relapsed AML

More Related